Increased conceptual switching by dopaminergic treatment in patients with Parkinson's disease

被引:5
|
作者
Tiedt, Hannes O. [1 ]
Ehlen, Felicitas [1 ,2 ]
Klostermann, Fabian [1 ,3 ]
机构
[1] Charite Univ Med Berlin, Dept Neurol, Motor & Cognit Grp, Campus Benjamin Franklin CBF, Hindenburgdamm 30, D-12203 Berlin, Germany
[2] Jud Krankenhaus Berlin, Dept Psychiat, Heinz Galinski Str 1, D-13347 Berlin, Germany
[3] Humboldt Univ, Berlin Sch Mind & Brain, Unter Linden 6, D-10099 Berlin, Germany
关键词
Parkinson's disease; Verbal fluency; Dopamine; Switches; Cluster; Semantic spreading activation; SPREADING-ACTIVATION THEORY; DEEP BRAIN-STIMULATION; VERBAL FLUENCY; WORKING-MEMORY; COGNITIVE PERFORMANCE; SEMANTIC ACTIVATION; DECISION-MAKING; MODULATION; LEVODOPA; OSCILLATIONS;
D O I
10.1016/j.bandc.2020.105611
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cognitive changes including reduced word production in verbal fluency (VF) tasks are frequently observed in Parkinson's disease (PD) with ambiguous effects of dopaminergic medication on these symptoms. Here, we studied the impact of dopaminergic medication on specific cognitive components underlying VF task performance in 21 participants with PD on their regular medication and following dopamine withdrawal compared with healthy controls. We used temporal cluster analysis (TCA) to differentiate phases of VF output relating to fast automatic lexical activation ('clusters') and slower attention-demanding shifts ('switches'). Dopaminergic medication led to increased switching and, in non-alternating VF tasks, to the formation of smaller and shorter word clusters. The number of switches was correlated with higher cognitive scores and showed an inverse relationship with VF error rates. Increased switching operations during VF task performance can be interpreted in view of nigrostriatal dopaminergic roles for balancing system state versus change propensities. The additional effect on word clustering suggests a modulation of semantic spreading activation mechanisms underlying lexical search, presumably involving non-nigrostriatal, e.g., mesocortical dopaminergic networks.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease
    Pagano, Gennaro
    Tan, Echo E.
    Haider, Janelle M.
    Bautista, Alyssa
    Tagliati, Michele
    PARKINSONISM & RELATED DISORDERS, 2015, 21 (02) : 120 - 125
  • [22] Pilot study of a new tool to optimise dopaminergic treatment in Parkinson's disease: the OPTIMIPARK questionnaire
    Manez-Miro, Jorge U.
    Vivancos-Matellano, Francisco
    Wetmore, John B.
    Martinez-Martin, Pablo
    REVISTA DE NEUROLOGIA, 2021, 72 (06) : 179 - 186
  • [23] Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease
    Devos, David
    Defebvre, L.
    Bordet, R.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 (04) : 407 - 421
  • [24] Clinical characteristics of fatigued Parkinson's patients and the response to dopaminergic treatment
    Fu, Rao
    Luo, Xiao-Guang
    Ren, Yan
    He, Zhi-Yi
    Lv, Hong
    TRANSLATIONAL NEURODEGENERATION, 2016, 5
  • [25] Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function
    MacDonald, Alex A.
    Monchi, Oury
    Seergobin, Ken N.
    Ganjavi, Hooman
    Tamjeedi, Ruzbeh
    MacDonald, Penny A.
    MOVEMENT DISORDERS, 2013, 28 (02) : 153 - 160
  • [26] Dopaminergic medication normalizes aberrant cognitive control circuit signalling in Parkinson's disease
    Cai, Weidong
    Young, Christina B.
    Yuan, Rui
    Lee, Byeongwook
    Ryman, Sephira
    Kim, Jeehyun
    Yang, Laurice
    Henderson, Victor W.
    Poston, Kathleen L.
    Menon, Vinod
    BRAIN, 2022, 145 (11) : 4042 - 4055
  • [27] Gait variability in Parkinson's disease: influence of walking speed and dopaminergic treatment
    Bryant, Mon S.
    Rintala, Diana H.
    Hou, Jyhgong G.
    Charness, Ann L.
    Fernandez, Angel L.
    Collins, Robert L.
    Baker, Jeff
    Lai, Eugene C.
    Protas, Elizabeth J.
    NEUROLOGICAL RESEARCH, 2011, 33 (09) : 959 - 964
  • [28] Verbal fluency in Parkinson's disease patients on/off dopamine medication
    Herrera, Elena
    Cuetos, Fernando
    Ribacoba, Renee
    NEUROPSYCHOLOGIA, 2012, 50 (14) : 3636 - 3640
  • [29] Behavioral disorders in Parkinson's disease: From pathophysiology to the mastery of dopaminergic treatment
    Thobois, S.
    Ardouin, C.
    Schmitt, E.
    Lhommee, E.
    Klinger, H.
    Xie, J.
    Lagrange, C.
    Kistner, A.
    Kombo, M. Aya
    Fleury, V.
    Poisson, A.
    Fraix, V.
    Broussolle, E.
    Pollak, P.
    Krack, P.
    REVUE NEUROLOGIQUE, 2010, 166 (10) : 816 - 821
  • [30] Parkinson's disease and RLS: the dopaminergic bridge
    Rye, DB
    SLEEP MEDICINE, 2004, 5 (03) : 317 - 328